Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA, Le Beau MM.
Qian Z, et al.
Chem Biol Interact. 2010 Mar 19;184(1-2):50-7. doi: 10.1016/j.cbi.2009.11.025. Epub 2009 Dec 1.
Chem Biol Interact. 2010.
PMID: 19958752
Free PMC article.
Review.
The most common subtype of t-AML ( approximately 75% of cases) develops after exposure to alkylating agents, and is characterized by loss or deletion of chromosome 5 and/or 7 [-5/del(5q), -7/del(7q)], and a poor outcome (median survival 8 months). In the University …
The most common subtype of t-AML ( approximately 75% of cases) develops after exposure to alkylating agents, and is characterized by loss or …